Temozolomide plus Survivin Vaccine for Growing Neuroendocrine Tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of a chemotherapy drug (temozolomide) and a vaccine (SurVaxM) that targets a protein called survivin found in some neuroendocrine tumors. It is for patients whose tumors have grown after at least one prior treatment, with the goal of slowing or stopping further growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a neuroendocrine tumor (NET) of the stomach, pancreas, or lung, or a neuroendocrine carcinoma (NEC) that is not small cell lung cancer.
- Your tumor has grown (on CT or MRI scans) in the last 12 months despite at least one prior treatment.
- Your tumor tissue tests positive for a protein called survivin.
- Your blood counts, kidney, and liver function are within a safe range.
- You are not pregnant or nursing, and are willing to use birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
This trial tests a combination of three drugs for people with advanced neuroendocrine carcinoma that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new virus-based treatment (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced neuroendocrine cancers that have gotten worse after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
This trial tests a new immunotherapy called PERCELLVAC-Sur that targets a protein (Survivin) found in glioblastoma tumors. It is given after standard radiation and chemotherapy, and the goal is to see if it helps the immune system fight the cancer more effectively.
This trial tests a new vaccine (UCPVax) with or without pembrolizumab (an immunotherapy) given after standard radiation and chemotherapy for people with a specific type of glioblastoma (MGMT unmethylated). The goal is to see if adding these treatments can help prevent the cancer from coming back.
Hear when a new Lung Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.